Gammopathy associated with advanced prostate carcinoma

Area of Science:

• Urology
• Immunology
• Oncology

Background:

• Proteinuria is frequently observed in prostate cancer patients.
• The presence and significance of elevated urinary immunoglobulin (Ig) levels in this population were previously uncharacterized.

Purpose of the Study:

• To investigate the prevalence of elevated urinary Ig levels in patients with androgen-dependent (AD) and androgen-independent (AI) prostate cancer.
• To characterize the type of immunoglobulin abnormalities present in these patients.

Main Methods:

• Collected first morning urine samples from 30 AD and 43 AI prostate cancer patients, and 15 healthy controls.
• Utilized sensitive solid-phase radioimmunoassay with polyclonal antibodies for IgG, IgA, and IgM detection.
• Employed specific heavy and light chain antibodies for further analysis of elevated Ig samples.

Main Results:

• Elevated urinary Ig levels were found in 33% of AD and 56% of AI prostate cancer patients.
• In the AI group, 71% of patients with prostatic squamous cell carcinoma (SCC) exhibited elevated urinary Igs.
• Analysis revealed polyclonal gammopathy in cases of high/moderate Ig elevation and monoclonal gammopathy (IgG class) in low elevations.

Conclusions:

• This study demonstrates a high frequency of abnormal urinary Ig levels in advanced prostate cancer patients.
• Elevated urinary immunoglobulins may serve as an indicator of disease progression and associated gammopathies in prostate cancer.